Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

Completed · Phase 2

Conditions studied: Liver, Cancer

In brief

Primary Aim Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma (cancer of the liver that can't be treated surgically). Secondary Aims 1. Determine the toxicity of this combination in this population. 2. Determine the survival of this patient cohort treated with the combination. 3. Determine the percent of patients with hepatocellular carcinoma who have a positive octreotide scan.

Key facts

Study ID
NCT00250796
Run by
University of New Mexico
People needed
12
Starts
2000-09-01
Expected to finish
2006-03-01
Last updated by the study team
2010-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.